ACADIA Pharmaceuticals Inc. vs Aterian Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Aterian Inc trades at $0.48 (market cap $5.22M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 969.3× Aterian Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ATER | |
|---|---|---|
Market Cap | $5.06B | $5.22M |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $1.39 |
52-Week Low | $20.06 | $0.36 |
Enterprise Value | $4.18B | $5.80M |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →